La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Tevogen Bio Holdings a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Tevogen Bio Holdings..

Tevogen Bio Holdings (NASDAQ:TVGN) Azioni, Catena delle Opzioni

Tevogen Bio Holdings

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Tevogen Bio Holdings Inc

Six years after the United Kingdom legalized medical marijuana, families struggling to obtain life-saving medicine through the National Health Service (NHS) returned to Westminster on Tuesday, demanding change. They displayed photos of their loved ones who experienced significant improvement with medical marijuana, <a href="https://businessofcannabis.com/parents-of-children-with-epilepsy-demand-urgent-nhs-reform-for-cannabis-access/">reports</a> the Business of Cannabis.
<h2 class="wp-block-heading">NHS Is Failing Patients</h2>
Parents of children suffering from treatment-resistant epilepsy say their children have achieved seizure freedom with medical marijuana, thanks to cannabis' effectiveness compared as to conventional treatments.
Those gathered at Westminster criticizes the lack of NHS prescriptions, especially for children with epilepsy. Only about 50 children have access to private prescriptions due to the limited availability of pediatric neurologists willing to prescribe. Campaigners argued that the NHS is failing patients and called for a change.
"When prescription cannabis was legalized six years ago, this was not the situation that patients were promised or expected," said co-chairs of the Cannabis Industry Council, Dr Callie Seaman and Jamie Bartley. "It's time for the NHS to take action to expand public funding of cannabis medicines. A clear pathway should be established for patients to access prescriptions via the NHS, while private prescriptions could also be reimbursed by the public purse."
A Department of Health and Social Care spokesperson said: "Licensed cannabis-based medicines are routinely funded by the NHS where there is clear evidence of their quality, safety, and effectiveness. The NHS is taking an evidence-based approach to unlicensed cannabis-based treatments to ensure they are proved safe and effective before they can be considered for roll out more widely."
The need for cannabis as medicine in the U.K. was first highlighted by two cases involving children with severe epilepsy: <a href="https://www.benzinga.com/markets/cannabis/22/12/30175937/only-cannabis-stops-harrys-constant-seizures-says-mom-he-gets-it-for-free-thanks-to-i-am-billy-c">Billy Caldwell</a> and Alfie Dingley who were both using cannabis low-dose THC oil to treat their seizures.
While it is possible to access medical marijuana through the NHS, this rarely occurs and only in severe cases of epilepsy, chemotherapy-induced nausea or certain cases of muscle stiffness associated with MS. Since medical marijuana is not widely available through the NHS, many families struggle to <a href="https://www.benzinga.com/markets/cannabis/23/10/35388605/europes-high-uk-parents-need-nhs-help-for-daughters-seizures-thc-mmj-flowers-in-switzerland-more" target="_blank" rel="noreferrer noopener">afford life-saving medicine</a> for their children.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41492967/medical-marijuana-for-chronic-pain-could-cut-uks-national-health-costs-by-5-19b-annually-improvi">Medical Marijuana For Chronic Pain Could Cut UK&#8217;s National Health Costs By $5.19B Annually, Improving Health Outcomes</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
Per a report, new figures show the lack of prescribing of both unlicensed and licensed medical marijuana medicines, such as <a href="https://www.benzinga.com/topic/epidiolex">Epidiolex</a> and Sativex in the NHS. According to the NHS Business Service Authority, ‘fewer than five' patients have an NHS prescription for unlicensed cannabis medicines, while the <a href="https://www.benzinga.com/markets/cannabis/24/10/41431474/as-uk-medical-marijuana-market-booms-cannabis-clinics-receive-good-practice-guide">private sectors booms</a> with more than 35,000 medical cannabis patients.
Epidiolex is the only FDA-approved prescription CBD treatment for severe forms of epilepsy. It was developed and produced by GW Pharmaceuticals, which was <a href="https://www.benzinga.com/general/biotech/21/05/20989747/jazz-pharmaceuticals-closes-on-acquisition-of-gw-pharma-adds-cbd-drug-epidiolex-to-portfolio" target="_blank" rel="noreferrer noopener">acquired by</a> Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) in 2021. Epidiolex was first approved for treating seizures connected to Lennox-Gastaut syndrome and Dravet syndrome. In 2022, Epidiolex was approved <a href="https://www.benzinga.com/markets/cannabis/20/08/16902941/fda-approves-cbd-meds-from-gw-pharmaceuticals-to-treat-seizures" target="_blank" rel="noreferrer noopener">for treating seizures related to tuberous sclerosis complex</a>.
A Freedom of Information request reveals that no NHS trusts have prescribed cannabis flower, and only 27% prescribe licensed medical marijuana medicines, such as Epidiolex.
Continue reading on <a href="https://businessofcannabis.com/parents-of-children-with-epilepsy-demand-urgent-nhs-reform-for-cannabis-access/">Business of Cannabis</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/23/06/32693057/uk-moms-concern-as-no-doctor-will-prescribe-cannabis-for-her-daughters-300-daily-seizures">UK Mom&#8217;s Concern As No Doctor Will Prescribe Cannabis For Her Daughter&#8217;s 300 Daily Seizures</a></li>
</ul>
Photo: Benzinga edit of images by Marcin Nowak and Kimzy Nanney on Unsplash

Cannabis

News

Eurozone

JAZZ

UK Parents Want National Health Service To Allow Cannabis For Children With Epilepsy

WIIM

EXPE

Expedia shares are trading higher after Benchmark maintained a Buy rating on the stock and raised its price target from $180 to $200.

Trading Ideas

Trump Media & Technology Group Shares Resumed Trade

FICO

Fair Isaac shares are trading higher after the company reported better-than-expected Q4 EPS and sales, with multiple analysts raising their price targets following the report.

EOG Resources shares are trading higher after the company reported better-than-expected Q3 EPS and sales, approved a $5 billion increase in its share repurchase authorization and raised its quarterly dividend.

Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Neutral and raises the price target from $30 to $38.

Price Target

Analyst Ratings

VERA

Wedbush Maintains Neutral on Vera Therapeutics, Raises Price Target to $38

PODD

Insulet shares are trading higher after the company reported better-than-expected Q3 financial results.

Truist Securities analyst Michael Swartz maintains United Parks &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRKS#NYSE">PRKS</a>) with a Buy and raises the price target from $60 to $64.

PRKS

Truist Securities Maintains Buy on United Parks & Resorts, Raises Price Target to $64

<a href="https://truthsocial.com/@realDonaldTrump/posts/113447949058695478" title="https://truthsocial.com/@realDonaldTrump/posts/113447949058695478">https://truthsocial.com/@realDonaldTrump/posts/113447949058695478</a>
<a href="https://truthsocial.com/@realDonaldTrump/posts/113447949058695478" title="https://truthsocial.com/@realDonaldTrump/posts/113447949058695478">https://truthsocial.com/@realDonaldTrump/posts/113447949058695478</a>

Government

Regulations

Legal

President-elect Donald Trump On Truth Social Posts "There are fake, untrue, and probably illegal rumors and/or statements made by, perhaps, market manipulators or short sellers, that I am interested in selling shares of Truth. THOSE RUMORS OR STATEMENTS ARE FALSE. I HAVE NO INTENTION OF SELLING!"

The KraneShares Electric Vehicles and Future Mobility Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KARS#NYSE">KARS</a>) has just hit a significant milestone, making a Golden Cross that has investors' attention piqued <a href="https://www.benzinga.com/electric-vehicles">and driving optimism</a>.
The ETF, which tracks the global transition to electric vehicles (EVs) and future mobility, is experiencing a surge, with its price moving above its five, 20 and 50-day exponential moving averages, signaling strong bullish momentum. 
The ETF is benefitting from its top-tier holdings, which include a mix of the EV sector&#8217;s biggest names: BYD Co Ltd (OTCPK: BYDDF), Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Geely Automobile Holdings Ltd (OTCPK: GELYF). It includes emerging players as well: Li Auto Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>), XPeng Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NASDAQ">XPEV</a>) and Arcadium Lithium PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTM#NYSE">ALTM</a>).
Read Also: <a href="https://www.benzinga.com/news/24/01/36508540/what-does-gms-electric-future-look-like-after-chevrolet-bolts-exit-last-years-delivery-numbers-could">What Does GM&#8217;s Electric Future Look Like After Chevrolet Bolt&#8217;s Exit? Last Year&#8217;s Delivery Numbers Could Give A Hint</a>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="627" height="452" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08091326/Screenshot-2024-11-08-at-5.32.55-PM.png" alt="" class="wp-image-637717" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08091326/Screenshot-2024-11-08-at-5.32.55-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08091326/Screenshot-2024-11-08-at-5.32.55-PM-300x216.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
<h2 class="wp-block-heading">KARS ETF Drives Up A Golden Cross</h2>
With a share price of $23.30, KARS is in the sweet spot for technical analysts. The 50-day simple moving average (SMA) has crossed over the 200-day SMA, triggering the Golden Cross. The ETF's eight-day SMA is at $22.52, the 20-day at $22.17 and the 50-day at $21.35. All these indicators show bullish signals, reinforcing the bullish sentiment surrounding the ETF.
It's currently trading at a price above its 200-day SMA of $21.08, further solidifying the case for upside potential.
The ETF is up 5% over the past five days and its 52-week high of $26.10 is well within reach. Despite a year-to-date decline of 7.32%, the recent uptick signals that KARS may be bouncing back, driven largely by the outperformance of its key holdings.
<h2 class="wp-block-heading">KARS Top Holdings Driving The Charge</h2>
KraneShares' KARS ETF is led by major EV players. BYD, the Chinese electric vehicle titan, is its top holding, making up 4.15% of the fund. Tesla (TSLA), a staple in the EV world, follows closely behind at 4.13%, while Geely, Xpeng and Li Auto continue to support the ETF's forward momentum. 
Tesla and BYD have been standouts this year, with BYD up 36.61% year-to-date and Tesla climbing 19.52%. 
Meanwhile, Li Auto has faced some struggles, down 25.96% this year, but the market is still hungry for electric vehicle exposure.
<h2 class="wp-block-heading">A Bullish Outlook, But Some Caution</h2>
While the Golden Cross signals bullish movement, KARS&#8217; Relative Strength Index (RSI) is currently at 58.9, suggesting the ETF is nearing overbought territory. With a MACD indicator of 0.33, there's still potential for more upside, but cautious optimism remains prudent as the market watches for any signs of cooling.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41825787/rivian-q3-earnings-highlights-revenue-eps-miss-ceo-confident-in-q4-gross-profit-r2-being-fundamenta">Rivian Q3 Earnings Highlights: Revenue, EPS Miss, CEO Confident In Q4 Gross Profit, R2 Being &#8216;Fundamental Driver&#8217; Of Growth</a></li>
</ul>
Image: Shutterstock

Specialty ETFs

Technicals

Signals

Tech

ETFs

ALTM

BYDDF

GELYF

KARS

TSLA

XPEV

KARS ETF Hits Golden Cross Powered By Tesla, Geely, Xpeng, Li

WLACU

Trading Halt: Halt status updated at 10:10:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Embraer-Empresa Brasileira De Aeronautica

Embraer shares are trading higher after the company reported better-than-expected Q3 financial results.

PTCT

PTC Therapeutics shares are trading higher after Baird raised its price target on the stock from $44 to $48.

Visionary Holdings Shares Resumed Trade

Truist Securities analyst Joseph Civello maintains Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) with a Hold and raises the price target from $8 to $11.

Truist Securities Maintains Hold on Under Armour, Raises Price Target to $11

Trump Media & Technology Group Shares Halted On Circuit Breaker To The Upside, Stock Now Up 10.4%

ACVA

ACV Auctions shares are trading higher after Piper Sandler raised its price target on the stock from $16 to $18.

Making a noteworthy insider sell on November 7, Leon Topalian, Chair at Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>), is reported in the latest SEC filing.
What Happened: Topalian opted to sell 11,000 shares of Nucor, according to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000073309/000112760224026679//Archives/edgar/data/73309/000112760224026679/0001127602-24-026679-index.htm">U.S. Securities and Exchange Commission</a> on Thursday. The transaction's total worth stands at $1,860,239.
The latest market snapshot at Friday morning reveals Nucor shares down by 3.12%, trading at $162.5.
<h3>About Nucor</h3>
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products, and raw materials, the steel mills segment derives maximum revenue. The steel mills segment includes carbon and alloy steel in sheet, bars, structural and plate; steel trading businesses; rebar distribution businesses; and Nucor's equity method investments in NuMit and NJSM.
<h3>Nucor: Delving into Financials</h3>
Negative Revenue Trend: Examining Nucor's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -15.17% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 10.18%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
</li>
<li>
Earnings per Share (EPS): Nucor's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 1.05.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.34.
Assessing Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: Nucor's P/E ratio of 15.51 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 1.24 is above industry norms, reflecting an elevated valuation for Nucor's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 7.78, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000073309">Check Out The Full List Of Nucor's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Sell Alert: Leon Topalian Cashes Out $1.86M In Nucor Stock

<ul>
<li>New data showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients treated with CTX-471 monotherapy.
<ul>
<li>Predictive biomarkers correlated with response and changes in pharmacodynamic markers were seen in patients treated with CTX-471, a novel anti-CD137 agonist antibody, in an analysis from the Phase 1 monotherapy study.</li>
</ul>
</li>
</ul>

Biotech

Events

General

CMPX

Compass Therapeutics Presents Biomarker Data Related To CTX-471 Clinical Activity At SITC Annual Meeting

A substantial insider sell was reported on November 7, by Jeffrey T Diehl, Board Member at Paylocity Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCTY#NASDAQ">PCTY</a>), based on the recent SEC filing.
What Happened: After conducting a thorough analysis, Diehl sold 17,729 shares of Paylocity Holding. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001591698/000159169824000292//Archives/edgar/data/1591698/000159169824000292/0001591698-24-000292-index.htm">U.S. Securities and Exchange Commission</a> on Thursday. The total transaction value is $3,443,121.
The latest market snapshot at Friday morning reveals Paylocity Holding shares down by 0.73%, trading at $209.18.
<h3>About Paylocity Holding</h3>
Paylocity is a provider of payroll and human capital management solutions servicing small- to midsize clients in the United States. The company was founded in 1997 and targets businesses with 10-5,000 employees and services about 39,000 clients as of fiscal 2024. Alongside core payroll services, Paylocity offers HCM solutions such as time and attendance and recruiting software as well as workplace collaboration and communication tools.
<h3>Financial Milestones: Paylocity Holding's Journey</h3>
Decline in Revenue: Over the 3 months period, Paylocity Holding faced challenges, resulting in a decline of approximately -12.5% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: With a high gross margin of 68.05%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): Paylocity Holding's EPS reflects a decline, falling below the industry average with a current EPS of 0.62.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.34.
Exploring Valuation Metrics Landscape:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 62.71, Paylocity Holding's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 8.87 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Paylocity Holding's EV/EBITDA ratio, surpassing industry averages at 35.68, positions it with an above-average valuation in the market.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>A Closer Look at Important Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates grant, award or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001591698">Check Out The Full List Of Paylocity Holding's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PCTY

Insider Unloading: Jeffrey T Diehl Sells $3.44M Worth Of Paylocity Holding Shares

Tevogen Bio Holdings (TVGN) has issued an announcement. Tevogen Bio Holdings Inc. has engaged in a securities purchase agreement, selling 600 share...

Tevogen Bio Holdings Announces Key Financial and Governance Moves

In this video, I review some amazing trades, one missed entry non-trade, a losing trade, and how not taking a high conviction trade can ruin them all.

A Lot Of Home Runs And One Ugly Strikeout; One New Swing Position

Tevogen Bio, Rani Therapeutics, and Expion360 are the 3 Penny Stocks to watch on October 15, 2024, based on&nbsp;TipRanks' Penny Stock Screener too...

3 Penny Stocks to Watch Now, 10/15/24

Tevogen (TVGN) Bio reported last week that Chief Scientific Officer Dr. Neal Flomenberg sold shares. "Tevogen's Chief Financial Officer, Kirti Desa...

Tevogen says CSO share sale 'solely' to satisfy payment of tax obligations

Tevogen Bio (TVGN) announces its Artificial Intelligence effort, Tevogen AI, has joined Microsoft (MSFT) for Startups. This partnership marks a sig...

Tevogen AI joins Microsoft for Startups

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: McDonald's (MCD) shares are continuing...

McDonald's down after outbreak, Starbucks slides after warning: Morning Buzz

Tevogen (TVGN) Bio provided additional guidance on the first clinical product of the company's proprietary ExacTcell technology, TVGN 489, designed...

Tevogen provides more guidance on ExacTcell technology

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Boeing (BA) will offer 90M shares of c...

Boeing to offer 90M common shares, Philips reports mixed Q3: Morning Buzz

Tevogen (TVGN) announced that it received written notice from the Listing Qualifications Staff of Nasdaq stating that the company has regained comp...

Tevogen regains compliance with Nasdaq

Tevogen Bio (TVGN) announced its Artificial Intelligence effort, Tevogen.AI, had partnered with Microsoft (MSFT) (MSFR) Using Microsoft's suite of ...

Tevogen leverages Microsoft partnership to deliver target identification for HPV

AAPL

AFRM

ALAB

ARLP

COIN

CORZ

CPAY

CSTM

EBAY

ENPH

EQNR

GLUE

GOOG

GOOGL

INTC

MSFT

MSTR

NPPXF

NTTYY

PLTR

PRCT

RANI

REAL

SAVE

SBUX

SNAP

TVGN

ULCC

XPON

Press Releases

Tevogen Bio's Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development

Early Movers: PRSO, TVGN, ZENA, CCTG, CRDL Stocks to Watch Today!

Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas

Contracts

Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity

Financing

Alpha Capital Appointed as Exclusive Financial Advisor to CD8 Technology to Secure Funding Up To $50 Million

Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company

Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs

Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support

Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920

Management

Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company's Novel Business Model as Key to Sustainable Success through Patient Affordability

Comments

Tevogen Bio Holdings

Tevogen Bio Holdings (TVGN) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO